Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Redwire Corporation (RDW) vs BIO-TECHNE Corp (TECH) Price & Performance

Redwire CorporationTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Redwire Corporation vs BIO-TECHNE Corp — how do they compare? Redwire Corporation trades at $8.97 (market cap $2.25B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 5× Redwire Corporation's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.

RDWTECH
Market Cap
$2.25B$11.16B
Sector
TechnologyHealth
52-Week High
$25.90$72.12
52-Week Low
$5.06$43.31
Enterprise Value
$2.31B$11.24B
Dividend Yield
0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Redwire Corporation

Redwire (RDW) trades at $8.60, down 1.78% with a bearish technical signal despite oversold RSI readings. The company shows strong revenue growth potential with a record $492 million backlog and a 1.92 book-to-bill ratio, but faces significant profitability challenges with a net income margin of -80.9% and consecutive earnings misses. Recent expansions in Indiana and Alabama highlight operational growth amid substantial cash burn from operations.

The stock presents a high-risk, high-reward opportunity with an 80% analyst buy rating and a $19.00 consensus price target implying over 120% upside. However, persistent losses, negative cash flow from operations, and potential dilution from a $500 million ATM offering pose substantial risks to near-term shareholder value.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.

The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Redwire Corporation

Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.

Read more on RDW

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH